Macrophage Migration Inhibitory Factor Deficiency Attenuates Macrophage Recruitment, Glomerulonephritis, and Lethality in MRL/<i>lpr</i> Mice
Alberta Hoi(Monash Health), Eric F. Morand(Novartis (Switzerland)), Pamela Hall(Monash University), Kim M. O’Sullivan(Centre for Inflammation Research), Leilani L. Santos(Royal Women's Hospital), A. Richard Kitching(Monash Health), Will G. James(Monash University), Jiro Yamana(Higashihiroshima Medical Center), Michael J. Hickey(Australian Regenerative Medicine Institute)
Cited by 133
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726